GET DAILY SIGNALSSelectQuote (SLQT) Q1 Results: Revenue Falls 15% but Profitability Gains Stand Out
Key Takeaways
- SelectQuote, Inc. (SLQT) reported first-quarter fiscal 2027 revenue of $280.0 million, a decline of about 15% from $328.8 million a year earlier, but slightly above the consensus estimate of roughly $278 million.
- The company's GAAP net loss narrowed to $20.3 million from $30.5 million, while diluted loss per share improved to $0.21 from $0.26 in the prior-year quarter.
- Adjusted EBITDA improved by $15 million year over year to a loss of $17.0 million.
- Management reaffirmed full-year fiscal 2027 guidance for revenue of $1.35 billion to $1.45 billion and at least $60 million of operating cash flow.
- Profitability per SelectRx member rose 60% year over year, reflecting efficiency gains from technology and artificial intelligence (AI) investments even as revenue softened.
Why This Quarter Matters
SelectQuote's first fiscal quarter is historically a seasonal investment period ahead of the Medicare Annual Enrollment Period (AEP), the fall window when seniors can switch Medicare Advantage and prescription drug plans. This quarter's report matters because it reveals how the company is balancing two competing forces: a deliberately smaller senior agent force and revenue pressure from the Inflation Reduction Act (IRA), a federal law that lowered some prescription drug pricing, against a push for stronger profitability and cash flow. With the stock trading at low levels and a reverse stock split vote scheduled for its November 10 annual meeting, investors are closely watching whether SelectQuote's margin and cash-flow improvements can outpace a shrinking top line. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Reported Results
For the first quarter of fiscal 2027 ended September 30, 2026, SelectQuote reported consolidated revenue of $280.0 million, down roughly 15% from $328.8 million in the prior-year period. The company attributed the decline to a smaller senior agent force and the impact of the Inflation Reduction Act on its Healthcare Services segment.
Net loss narrowed to $20.3 million from $30.5 million a year earlier, and diluted loss per share from continuing operations improved to $0.21 from $0.26. Adjusted EBITDA improved $15 million year over year to a loss of $17.0 million, and cash used in operations declined to $17.2 million from $21.6 million. Revenue edged past the approximately $278 million consensus estimate, while the per-share loss came in ahead of expectations.
By segment, Senior revenue fell 14% to $50.8 million, while its adjusted EBITDA loss improved to $12.3 million from $21.0 million. Healthcare Services revenue declined 16% to $186.3 million, but adjusted EBITDA rose 56% to $11.2 million, and profitability per SelectRx member climbed 60% to $107.6. The Life segment generated $42.8 million in revenue with adjusted EBITDA of $7.3 million, as its margin expanded to 17% from 12%.
Market Reaction and Investor Sentiment
Shares rallied sharply following the release, as investors rewarded the year-over-year improvement in adjusted EBITDA and operating cash flow despite the revenue decline. The results reinforced the view that SelectQuote is prioritizing profitability and cash generation over volume, a strategy that has drawn scrutiny given the shrinking top line. Still, sentiment remains cautious around the company's balance sheet and listing status, with a reverse stock split proposal set for a shareholder vote on November 10. The upbeat margin story, combined with early signs of strong customer engagement heading into AEP, appeared to offset concerns about lower Medicare Advantage policy volumes for now.
Forward Outlook and Key Factors to Monitor
Looking ahead, investors will focus on how SelectQuote performs during the Medicare AEP and Open Enrollment Period, which drive the bulk of its Senior and SelectRx revenue in the second and third fiscal quarters. Management described the upcoming season as another dynamic recovery year for Medicare Advantage, citing elevated plan terminations and benefit changes that could increase demand for its agent-led model.
Key factors to watch include approved Medicare Advantage policy volumes, the lifetime value (LTV) of commissions per approved policy, and the recapture rate for beneficiaries whose plans were terminated. In Healthcare Services, the ramp of the new Olathe, Kansas distribution facility and the in-house pharmacy management system could support the company's target of roughly doubling segment margins in fiscal 2027.
On the balance sheet, investors should monitor operating cash flow progress toward the $60 million-plus target, along with any updates on the preferred dividend and the outcome of the reverse stock split vote. The company's own guidance still implies continued revenue shrinkage, so the central question remains whether efficiency and cash-flow gains can sustain the stock's momentum without a return to top-line growth. From what I see, the focus on margins is what matters most right now.
My Experience with Tickeron’s AI Tools
I regularly turn to Tickeron’s AI Screener when analyzing earnings releases like this one. It lets me quickly filter for stocks showing similar margin expansion patterns or cash-flow trends, which helps put SelectQuote’s results in broader context without spending hours on manual screens. The tool has become a standard part of my process for spotting comparable opportunities across the sector.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Momentum Indicator for SLQT turns positive, indicating new upward trend
SLQT saw its Momentum Indicator move above the 0 level on October 27, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 92 similar instances where the indicator turned positive. In 82 of the 92 cases, the stock moved higher in the following days. The odds of a move higher are at 89%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where SLQT's RSI Oscillator exited the oversold zone, 32 of 44 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 73%.
The Moving Average Convergence Divergence (MACD) for SLQT just turned positive on September 29, 2026. Looking at past instances where SLQT's MACD turned positive, the stock continued to rise in 37 of 43 cases over the following month. The odds of a continued upward trend are 86%.
Following a +14.85% 3-day Advance, the price is estimated to grow further. Considering data from situations where SLQT advanced for three days, in 204 of 254 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SLQT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
SLQT broke above its upper Bollinger Band on November 02, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for SLQT entered a downward trend on November 03, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 4 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.206) is normal, around the industry mean (2.673). P/E Ratio (-6.833) is within average values for comparable stocks, (18.899). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (8.322). Dividend Yield (0.000) settles around the average of (0.042) among similar stocks. P/S Ratio (0.058) is also within normal values, averaging (2.968).
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 85 (best 1 - 100 worst), indicating slightly worse than average price growth. SLQT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 92 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SLQT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 85, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a technology-enabled, direct-to-consumer distribution platform that provides consumers with a transparent and convenient venue to shop for complex senior health, life and auto & home insurance policies from a curated panel of insurance carriers
Industry InsuranceBrokersServices
Advertisement